SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 23, 2002
The Medicines Company
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-31191 04-3324394
------------------------ ------------------------ --------------------------
(State or Other (Commission (I.R.S. Employer
Jurisdiction File Number) Identification No.)
of Incorporation)
5 Sylvan Way, Suite 200
Parsippany, New Jersey 07054
--------------------------------------------- --------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (973) 656-1616
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS.
On April 23, 2002, The Medicines Company announced its financial results
for the first quarter of 2002 and the naming of a new Chief Financial Officer.
In a separate announcement on April 23, 2002, The Medicines Company announced
that it had filed a Form S-3 Shelf Registration Statement registering 4,000,000
shares of its common stock.
The full text of the press releases issued in connection with the
announcements is filed as Exhibit 99.1 and Exhibit 99.2 to this Current Report
on Form 8-K and is incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
Exhibit No. Description
----------- -----------
99.1 Press release dated April 23, 2002
entitled "The Medicines Company
Reports First Quarter 2002 Financial
Results, Names New Chief Financial
Officer."
99.2 Press release dated April 23, 2002
entitled "The Medicines Company Files
Shelf Registration Statement."
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: April 25, 2002 THE MEDICINES COMPANY
By: /s/ Steven H. Koehler
------------------------------------
Steven H. Koehler
Vice President and Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
99.1 Press release dated April 23, 2002
entitled "The Medicines Company
Reports First Quarter 2002 Financial
Results, Names New Chief Financial
Officer."
99.2 Press release dated April 23, 2002
entitled "The Medicines Company Files
Shelf Registration Statement."